Sellas Life Sciences Group Inc (SLS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.45 (-0.69%), Market cap $1.41B, 52-week low–high $1.39 ~ $7.59.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet
Financial statements, price targets, institutional (13F) holdings and related news for Sellas Life Sciences Group Inc are updated in real time on BlackAll Trade.
Sellas Life Sciences Group Inc trades at $11.45 (-0.69%). Real-time quotes and charts are available on BlackAll Trade.
Sellas Life Sciences Group Inc has a market cap of about $1.41B.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's l